Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered biologics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback